Advertisement

The Latest

When compared to chemotherapy, a drug targeting oncogenic RAS mutations extended overall and progression-free survival for patients with metastatic pancreatic cancer, according to a study published May 31 in The New England Journal of Medicine. The third-leading cause of cancer…

New York City-based Memorial Sloan Kettering Cancer Center has filed a lawsuit against GE HealthCare, claiming the company infringed its patents for imaging technology. Memorial Sloan Kettering alleges that GE HealthCare’s “MotionFree” technology built into several of its PET/CT scanner…

Boston-based Dana-Farber Cancer Institute has named Kathleen Keavany senior vice president of ambulatory care. In the newly created role, Ms. Keavany will oversee all adult ambulatory services and work alongside leadership at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center for…

Miami-based Baptist Health Herbert Wertheim Cancer Institute has named Alia Abdulla, DO, chief of breast surgical oncology in Plantation, Fla. Dr. Abdulla serves as a clinical assistant professor of surgery at Miami-based Florida International University and Fort Lauderdale, Fla.-based Nova…

An androgen receptor inhibitor was found to improve rates of metastasis-free survival among prostate cancer patients when combined with androgen deprivation therapy, according to a study published May 31 in The New England Journal of Medicine.  The study was led…

Seattle-based Fred Hutch Cancer Center has appointed Nida Shekhani executive vice president and chief strategy and clinical growth officer.  Ms. Shekhani will step into the role July 1, according to a June 3 LinkedIn post from the cancer center.  She…

New York City-based Memorial Sloan Kettering Cancer Center has appointed Martin Weiser, MD, chair of the department of surgery.  Dr. Weiser joined Memorial Sloan Kettering 25 years ago and has served as acting department chair for the past 10 months,…

The American Cancer Society added Guardant Health’s Shield blood test to its updated colorectal cancer screening guidelines, published May 27. The Palo Alto, Calif.-based precision oncology company said the ACS now recommends Shield for patients who decline or have not…

Advertisement